Human iPSC-derived iMSCs improve bone regeneration in mini-pigs

Abstract

Autologous bone marrow concentrate (BMC) and mesenchymal stem cells (MSCs) have beneficial effects on the healing of bone defects. To address the shortcomings associated with the use of primary MSCs, induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) have been proposed as an alternative. The aim of this study was to investigate the bone regeneration potential of human iMSCs combined with calcium phosphate granules (CPG) in critical-size defects in the proximal tibias of mini-pigs in the early phase of bone healing compared to that of a previously reported autograft treatment and treatment with a composite made of either a combination of autologous BMC and CPG or CPG alone. iMSCs were derived from iPSCs originating from human fetal foreskin fibroblasts (HFFs). They were able to differentiate into osteoblasts in vitro, express a plethora of bone morphogenic proteins (BMPs) and secrete paracrine signaling-associated cytokines such as PDGF-AA and osteopontin. Radiologically and histomorphometrically, HFF-iMSC + CPG transplantation resulted in significantly better osseous consolidation than the transplantation of CPG alone and produced no significantly different outcomes compared to the transplantation of autologous BMC + CPG after 6 weeks. The results of this translational study imply that iMSCs represent a valuable future treatment option for load-bearing bone defects in humans.

References

[1] Faour O, Dimitriou R, Cousins CA, Giannoudis PV. The use of bone graft substitutes in large cancellous voids: any specific needs? Injury, 2011, 42:87-90

[2] Herten M et al. Bone marrow concentrate for autologous transplantation in minipigs. Characterization and osteogenic potential of mesenchymal stem cells. Vet. Comp. Orthop. Traumatol., 2013, 26:34-41

[3] Grayson WL et al. Stromal cells and stem cells in clinical bone regeneration. Nat. Rev. Endocrinol., 2015, 11:140-150

[4] Hakimi, M. et al. The composite of bone marrow concentrate and PRP as an alternative to autologous bone grafting. PLoS ONE 9, e100143 (2014).

[5] Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet., 1987, 20:263-272

[6] Pittenger MF et al. Multilineage potential of adult human mesenchymal stem cells. Science, 1999, 284:143-147

[7] Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells, 2001, 19:180-192

[8] Dominici M et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006, 8:315-317

[9] Bhumiratana S et al. Tissue-engineered autologous grafts for facial bone reconstruction. Sci. Transl. Med., 2016, 8:343ra83

[10] Sheyn D et al. Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects. Stem Cells Transl. Med., 2016, 5:1447-1460

[11] Duscher D et al. Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells. Sci. Rep., 2014, 4

[12] Yang YK, Ogando CR, Wang See C, Chang TY, Barabino GA. Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Res Ther., 2018, 9:131

[13] Palumbo S, Tsai TL, Li WJ. Macrophage migration inhibitory factor regulates AKT signaling in hypoxic culture to modulate senescence of human mesenchymal stem cells. Stem Cells Dev., 2014, 23:852-865

[14] Frobel J et al. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Rep., 2014, 3:414-422

[15] Spitzhorn LS et al. Transplanted human pluripotent stem cell-derived mesenchymal stem cells support liver regeneration in gunn rats. Stem Cells Dev., 2018, 27:1702-1714

[16] Wang X et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Rep., 2014, 3:115-130

[17] Chen YS et al. Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl. Med, 2012, 1:83-95

[18] Schlegel KA, Lang FJ, Donath K, Kulow JT, Wiltfang J. The monocortical critical size bone defect as an alternative experimental model in testing bone substitute materials. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod., 2006, 102:7-13

[19] Li Y et al. Bone defect animal models for testing efficacy of bone substitute biomaterials. J. Orthop. Transl., 2015, 3:95-104

[20] Quarto R et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med., 2001, 344:385-386

[21] Warnke PH et al. Growth and transplantation of a custom vascularised bone graft in a man. Lancet, 2004, 364:766-770

[22] Ismail et al. Mesenchymal stem cell implantation in atrophic nonunion of the long bones: a translational study. Bone Jt. Res., 2016, 5:287-293

[23] Reichert JC et al. A tissue engineering solution for segmental defect regeneration in load-bearing long bones. Sci. Transl. Med., 2012, 4:141ra93

[24] Lian Q et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation, 2010, 121:1113-1123

[25] Takahashi K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 131:861-872

[26] Komori T. Requisite roles of Runx2 and Cbfb in skeletal development. J. Bone Min. Metab., 2003, 21:193-197

[27] Zhou W, Liu Q, Xu B. Improvement of bone defect healing in rats via mesenchymal stem cell supernatant. Exp. Ther. Med., 2018, 15:1500-1504

[28] Li CL et al. Human iPSC-MSC-derived xenografts modulate immune responses by inhibiting the cleavage of caspases. Stem Cells, 2017, 35:1719-1732

[29] Jungbluth P et al. Concentration of platelets and growth factors in platelet-rich plasma from Goettingen minipigs. GMS Inter. Plast. Reconstr. Surg. Dgpw., 2014, 3:Doc11

[30] Wang P et al. Bone tissue engineering via nanostructured calcium phosphate biomaterials and stem cells. Bone Res., 2014, 2:14017

[31] de Peppo GM, Vunjak-Novakovic G, Marolt D. Cultivation of human bone-like tissue from pluripotent stem cell-derived osteogenic progenitors in perfusion bioreactors. Methods Mol. Biol., 2014, 1202:173-184

[32] Schubert T et al. The enhanced performance of bone allografts using osteogenic-differentiated adipose-derived mesenchymal stem cells. Biomaterials, 2011, 32:8880-8891

[33] Tas AC. Preparation of porous apatite granules from calcium phosphate cement. J. Mater. Sci. Mater. Med, 2008, 19:2231-2239

[34] Weiss P et al. Synchrotron X-ray microtomography (on a micron scale) provides three-dimensional imaging representation of bone ingrowth in calcium phosphate biomaterials. Biomaterials, 2003, 24:4591-4601

[35] Bohner M, Baumgart F. Theoretical model to determine the effects of geometrical factors on the resorption of calcium phosphate bone substitutes. Biomaterials, 2004, 25:3569-3582

[36] Zhang J, Liu W, Schnitzler V, Tancret F, Bouler JM. Calcium phosphate cements for bone substitution: chemistry, handling and mechanical properties. Acta Biomater., 2014, 10:1035-1049

[37] Jungbluth P et al. The early phase influence of bone marrow concentrate on metaphyseal bone healing. Injury, 2013, 44 Oct 1285-1294

[38] Kröpil P et al. Cone beam CT in assessment of tibial bone defect healing: an animal study. Acad. Radiol., 2012, 19:320-325

[39] Riegger C et al. Quantitative assessment of bone defect healing by multidetector CT in a pig model. Skelet. Radiol., 2012, 41:531-537

[40] Li X et al. iPSC-derived mesenchymal stem cells exert SCF-dependent recovery of cigarette smoke-induced apoptosis/proliferation imbalance in airway cells. J. Cell Mol. Med., 2017, 21:265-277

[41] Li X et al. Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways. J. Allergy Clin. Immunol., 2018, 141:1634-1645

[42] Schmidt-Bleek K, Willie BM, Schwabe P, Seemann P, Duda GN. BMPs in bone regeneration: Less is more effective, a paradigm-shift. Cytokine Growth Factor Rev., 2016, 27:141-148

[43] Ding Y et al. Rap1 deficiency-provoked paracrine dysfunction impairs immunosuppressive potency of mesenchymal stem cells in allograft rejection of heart transplantation. Cell Death Dis., 2018, 9

[44] Zhang Y et al. Absence of NUCKS augments paracrine effects of mesenchymal stem cells-mediated cardiac protection. Exp. Cell Res., 2017, 356:74-84

[45] Bohndorf M et al. Derivation and characterization of integration-free iPSC line ISRM-UM51 derived from SIX2-positive renal cells isolated from urine of an African male expressing the CYP2D6 *4/*17 variant which confers intermediate drug metabolizing activity. Stem Cell Res., 2017, 25:18-21

[46] Gentleman RC et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol., 2004, 5

[47] Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 2004, 20:307-315

[48] Rahman MS et al. The presence of human mesenchymal stem cells of renal origin in amniotic fluid increases with gestational time. Stem Cell Res Ther., 2018, 9:113

[49] Hakimi M et al. Combined use of platelet-rich plasma and autologous bone grafts in the treatment of long bone defects in mini-pigs. Injury, 2010, 41:717-723

[50] Jungbluth P et al. Platelet-rich plasma on calcium phosphate granules promotes metaphyseal bone healing in mini-pigs. J. Orthop. Res., 2010, 28:1448-1455

Funding

German Academic Exchange Service | German Academic Exchange Service London (Deutscher Akademischer Austauschdienst London)(DAAD-91607303)

Heinrich-Heine-Universität Düsseldorf (Heinrich Heine University Düsseldorf)

Deutscher Akademischer Austauschdienst (German Academic Exchange Service)(DAAD-91607303)